;PMID: 10777194
;source_file_737.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..43] = [t:0..43]
;1)sentence:[e:48..187] = [t:48..187]
;2)section:[e:191..313] = [t:191..313]
;3)section:[e:317..405] = [t:317..405]
;4)sentence:[e:409..609] = [t:409..609]
;5)sentence:[e:610..768] = [t:610..768]
;6)sentence:[e:769..964] = [t:769..964]
;7)sentence:[e:965..1080] = [t:965..1080]
;8)sentence:[e:1081..1214] = [t:1081..1214]
;9)sentence:[e:1215..1467] = [t:1215..1467]
;10)section:[e:1471..1516] = [t:1471..1516]

;section 0 Span:0..43
;J Clin Gastroenterol  2000 Apr;30(3):307-10
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..6] Clin) (NNP:[7..20] Gastroenterol)
        (CD:[22..26] 2000) (CC:[27..34] Apr;30-LRB-) (CD:[34..35] 3)
        (-RRB-:[35..36] -RRB-) (CD:[36..40] :307) (::[40..41] -)
        (CD:[41..43] 10)))

;sentence 1 Span:48..187
;Nonfunctioning islet cell carcinoma of the pancreas with high serum CEA & 
;CA19-9, K-ras codon 12 mutation, and microsatellite instability.
;[48..99]:malignancy:"Nonfunctioning islet cell carcinoma of the pancreas"
;[110..119]:gene-protein:"serum CEA"
;[123..129]:gene-protein:"CA19-9"
;[131..136]:gene-rna:"K-ras"
;[137..145]:variation-location:"codon 12"
;[146..154]:variation-event:"mutation"
(SENT
  (NP-HLN
    
    (NP (JJ:[48..62] Nonfunctioning)
      (NML (NN:[63..68] islet) (NN:[69..73] cell))
      (NN:[74..83] carcinoma))
    (PP (IN:[84..86] of)
      (NP (DT:[87..90] the) (NN:[91..99] pancreas)))
    (PP (IN:[100..104] with)
      (NP
        (NP
          (NP
            (ADJP-2 (JJ:[105..109] high))
            
            (NML-1 (NN:[110..115] serum))
            (NN:[116..119] CEA))
          (CC:[120..121] &)
          (NP
            (ADJP-2 (-NONE-:[121..121] *P*))
            (NML-1 (-NONE-:[121..121] *P*))
            (NN:[123..129] CA19-9)))
        (,:[129..130] ,)
        (NP (NN:[131..136] K-ras)
          (NML (NN:[137..142] codon) (CD:[143..145] 12))
          (NN:[146..154] mutation))
        (,:[154..155] ,) (CC:[156..159] and)
        (NP (NN:[160..174] microsatellite) (NN:[175..186] instability))))
    (.:[186..187] .)))

;section 2 Span:191..313
;Okai T, Kawashima A, Watanabe H, Takahashi Y, Sakai J, Ohtsubo K, Motoo Y, 
;Matsui O, Murakami S, Nakabayashi H, Sawabu N.
(SEC
  (FRAG (NNP:[191..195] Okai) (NNP:[196..197] T) (,:[197..198] ,)
        (NNP:[199..208] Kawashima) (NNP:[209..210] A) (,:[210..211] ,)
        (NNP:[212..220] Watanabe) (NNP:[221..222] H) (,:[222..223] ,)
        (NNP:[224..233] Takahashi) (NNP:[234..235] Y) (,:[235..236] ,)
        (NNP:[237..242] Sakai) (NNP:[243..245] J,) (NNP:[246..253] Ohtsubo)
        (NNP:[254..255] K) (,:[255..256] ,) (NNP:[257..262] Motoo)
        (NNP:[263..264] Y) (,:[264..265] ,) (NNP:[267..273] Matsui)
        (NNP:[274..275] O) (,:[275..276] ,) (NNP:[277..285] Murakami)
        (NNP:[286..288] S,) (NNP:[289..300] Nakabayashi) (NNP:[301..302] H)
        (,:[302..303] ,) (NNP:[304..310] Sawabu) (NNP:[311..313] N.)))

;section 3 Span:317..405
;Department of Internal Medicine, Cancer Research Institute, Kanazawa
;University,  Japan.
(SEC
  (FRAG (NNP:[317..327] Department) (IN:[328..330] of) (NNP:[331..339] Internal)
        (NNP:[340..348] Medicine) (,:[348..349] ,) (NNP:[350..356] Cancer)
        (NNP:[357..365] Research) (NNP:[366..375] Institute) (,:[375..376] ,)
        (NNP:[377..385] Kanazawa) (NNP:[386..396] University) (IN:[396..397] ,)
        (NNP:[399..404] Japan) (.:[404..405] .)))

;sentence 4 Span:409..609
;A 55-year-old man with nonfunctioning islet cell carcinoma showing elevation
;of  serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9
;(CA19-9)  levels is described with genetic analyses.
;[432..467]:malignancy:"nonfunctioning islet cell carcinoma"
;[490..520]:gene-protein:"serum carcinoembryonic antigen"
;[522..525]:gene-protein:"CEA"
;[531..556]:gene-protein:"carbohydrate antigen 19-9"
;[558..564]:gene-protein:"CA19-9"
(SENT
  (S
    (NP-SBJ-3
      (NP (DT:[409..410] A)
        (ADJP
          (NML (CD:[411..413] 55) (HYPH:[413..414] -) (NN:[414..418] year))
          (HYPH:[418..419] -) (JJ:[419..422] old))
        (NN:[423..426] man))
      (PP (IN:[427..431] with)
        (NP
          (NP (JJ:[432..446] nonfunctioning)
            (NML (NN:[447..452] islet) (NN:[453..457] cell))
            (NN:[458..467] carcinoma))
          (VP (VBG:[468..475] showing)
            (NP
              (NP (NN:[476..485] elevation))
              (PP (IN:[486..488] of)
                (NP
                  (NP
                    (NML-2 (NN:[490..495] serum))
                    (NML
                      (NML (JJ:[496..512] carcinoembryonic)
                           (NN:[513..520] antigen))
                      (NML (-LRB-:[521..522] -LRB-) (NN:[522..525] CEA)
                           (-RRB-:[525..526] -RRB-)))
                    (NML-1 (-NONE-:[526..526] *P*)))
                  (CC:[527..530] and)
                  (NP
                    (NML-2 (-NONE-:[530..530] *P*))
                    (NML
                      (NML (NN:[531..543] carbohydrate) (NN:[544..551] antigen)
                           (NN:[552..556] 19-9))
                      (NML (-LRB-:[557..558] -LRB-) (NN:[558..564] CA19-9)
                           (-RRB-:[564..565] -RRB-)))
                    (NML-1 (NNS:[567..573] levels))))))))))
    (VP (VBZ:[574..576] is)
      (VP (VBN:[577..586] described)
        (NP-3 (-NONE-:[586..586] *))
        (PP (IN:[587..591] with)
          (NP (JJ:[592..599] genetic) (NNS:[600..608] analyses)))))
    (.:[608..609] .)))

;sentence 5 Span:610..768
;Pathological examination of the  resected specimen revealed two independent
;islet cell carcinomas, one in the  body and the other in the tail of the
;pancreas.
;[686..707]:malignancy:"islet cell carcinomas"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[610..622] Pathological) (NN:[623..634] examination))
      (PP (IN:[635..637] of)
        (NP (DT:[638..641] the) (VBN:[643..651] resected)
            (NN:[652..660] specimen))))
    (VP (VBD:[661..669] revealed)
      (NP
        (NP (CD:[670..673] two) (JJ:[674..685] independent)
          
          (NML (NN:[686..691] islet) (NN:[692..696] cell))
          (NNS:[697..707] carcinomas))
        (,:[707..708] ,)
        (NP
          (NP
            (NP (CD:[709..712] one))
            (PP-LOC (IN:[713..715] in)
              (NP
                (NP (DT:[716..719] the) (NN:[721..725] body))
                (PP-1 (-NONE-:[725..725] *RNR*)))))
          (CC:[726..729] and)
          (NP
            (NP (DT:[730..733] the) (JJ:[734..739] other))
            (PP-LOC (IN:[740..742] in)
              (NP
                (NP (DT:[743..746] the) (NN:[747..751] tail))
                (PP-1 (-NONE-:[751..751] *RNR*)))))
          (PP-1 (IN:[752..754] of)
            (NP (DT:[755..758] the) (NN:[759..767] pancreas))))))
    (.:[767..768] .)))

;sentence 6 Span:769..964
;It was proved  immunohistochemically that the tumor cells, particularly those
;in the tail, were  immunoreactive to CEA and CA 19-9 and had the property of
;duct cells, as well as  endocrine cells.
;[815..826]:malignancy:"tumor cells"
;[884..887]:gene-protein:"CEA"
;[892..899]:gene-protein:"CA 19-9"
(SENT
  (S
    (NP-SBJ-1
      (NP (PRP:[769..771] It))
      (SBAR-2 (-NONE-:[771..771] *EXP*)))
    (VP (VBD:[772..775] was)
      (VP (VBN:[776..782] proved)
        (NP-1 (-NONE-:[782..782] *))
        (ADVP-MNR (RB:[784..805] immunohistochemically))
        (SBAR-2 (IN:[806..810] that)
          (S
            (NP-SBJ
              (NP (DT:[811..814] the)
                 (NN:[815..820] tumor) (NNS:[821..826] cells))
              (,:[826..827] ,)
              (ADVP (RB:[828..840] particularly)
                (NP
                  (NP (DT:[841..846] those))
                  (PP (IN:[847..849] in)
                    (NP (DT:[850..853] the) (NN:[854..858] tail))))))
            (,:[858..859] ,)
            (VP
              (VP (VBD:[860..864] were)
                (ADJP-PRD (JJ:[866..880] immunoreactive)
                  (PP (TO:[881..883] to)
                    (NP
                      (NP (NN:[884..887] CEA))
                      (CC:[888..891] and)
                      (NP (NN:[892..894] CA) (NN:[895..899] 19-9))))))
              (CC:[900..903] and)
              (VP (VBD:[904..907] had)
                (NP
                  (NP (DT:[908..911] the) (NN:[912..920] property))
                  (PP (IN:[921..923] of)
                    (NP
                      (NP (NN:[924..928] duct) (NNS:[929..934] cells))
                      (,:[934..935] ,)
                      (CONJP (RB:[936..938] as) (RB:[939..943] well)
                             (IN:[944..946] as))
                      (NP (JJ:[948..957] endocrine) (NNS:[958..963] cells)))))))))))
    (.:[963..964] .)))

;sentence 7 Span:965..1080
;Gastrin was demonstrated immunohistochemically in these tumor  cells,
;although its level in serum was not elevated.
;[965..972]:gene-protein:"Gastrin"
;[1021..1033]:malignancy:"tumor  cells"
(SENT
  (S
    (NP-SBJ-2 (NN:[965..972] Gastrin))
    (VP (VBD:[973..976] was)
      (VP (VBN:[977..989] demonstrated)
        (NP-2 (-NONE-:[989..989] *))
        (ADVP-MNR (RB:[990..1011] immunohistochemically))
        (PP-LOC (IN:[1012..1014] in)
          (NP (DT:[1015..1020] these)
             (NN:[1021..1026] tumor) (NNS:[1028..1033] cells)))
        (,:[1033..1034] ,)
        (SBAR-ADV (IN:[1035..1043] although)
          (S
            (NP-SBJ-1
              (NP (PRP$:[1044..1047] its) (NN:[1048..1053] level))
              (PP-LOC (IN:[1054..1056] in)
                (NP (NN:[1057..1062] serum))))
            (VP (VBD:[1063..1066] was) (RB:[1067..1070] not)
              (VP (JJ:[1071..1079] elevated)
                (NP-1 (-NONE-:[1079..1079] *))))))))
    (.:[1079..1080] .)))

;sentence 8 Span:1081..1214
;Genetic analyses of the  fresh specimens from the tumor in the body revealed
;K-ras codon 12 mutation and  microsatellite instability.
;[1131..1136]:malignancy:"tumor"
;[1158..1163]:gene-rna:"K-ras"
;[1164..1172]:variation-location:"codon 12"
;[1173..1181]:variation-event:"mutation"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1081..1088] Genetic) (NNS:[1089..1097] analyses))
      (PP (IN:[1098..1100] of)
        (NP
          (NP (DT:[1101..1104] the) (JJ:[1106..1111] fresh)
              (NNS:[1112..1121] specimens))
          (PP (IN:[1122..1126] from)
            (NP
              (NP (DT:[1127..1130] the) (NN:[1131..1136] tumor))
              (PP-LOC (IN:[1137..1139] in)
                (NP (DT:[1140..1143] the) (NN:[1144..1148] body))))))))
    (VP (VBD:[1149..1157] revealed)
      (NP
        (NP (NN:[1158..1163] K-ras)
          (NML (NN:[1164..1169] codon) (CD:[1170..1172] 12))
          (NN:[1173..1181] mutation))
        (CC:[1182..1185] and)
        (NP (NN:[1187..1201] microsatellite) (NN:[1202..1213] instability))))
    (.:[1213..1214] .)))

;sentence 9 Span:1215..1467
;These findings are consistent with its progressive  clinical course and
;strongly suggest that these tumors originate, not from the  islet cells of
;Langerhans, but from protodifferentiated cells, capable of giving  rise to
;all the pancreatic cell types.
;[1315..1321]:malignancy:"tumors"
(SENT
  (S
    (NP-SBJ (DT:[1215..1220] These) (NNS:[1221..1229] findings))
    (VP
      (VP (VBP:[1230..1233] are)
        (ADJP-PRD (JJ:[1234..1244] consistent)
          (PP (IN:[1245..1249] with)
            (NP (PRP$:[1250..1253] its) (JJ:[1254..1265] progressive)
                (JJ:[1267..1275] clinical) (NN:[1276..1282] course)))))
      (CC:[1283..1286] and)
      (VP
        (ADVP (RB:[1287..1295] strongly))
        (VBP:[1296..1303] suggest)
        (SBAR (IN:[1304..1308] that)
          (S
            (NP-SBJ (DT:[1309..1314] these) (NNS:[1315..1321] tumors))
            (VP (VBP:[1322..1331] originate) (,:[1331..1332] ,)
              (PP (RB:[1333..1336] not)
                (PP (IN:[1337..1341] from)
                  (NP
                    (NP (DT:[1342..1345] the) (NN:[1347..1352] islet)
                        (NNS:[1353..1358] cells))
                    (PP (IN:[1359..1361] of)
                      (NP (NNP:[1362..1372] Langerhans)))))
                (,:[1372..1373] ,) (CC:[1374..1377] but)
                (PP (IN:[1378..1382] from)
                  (NP
                    (NP (JJ:[1383..1402] protodifferentiated)
                        (NNS:[1403..1408] cells))
                    (,:[1408..1409] ,)
                    (ADJP (JJ:[1410..1417] capable)
                      (PP (IN:[1418..1420] of)
                        (S-NOM
                          (NP-SBJ (-NONE-:[1420..1420] *))
                          (VP (VBG:[1421..1427] giving)
                            (NP-CLR (NN:[1429..1433] rise))
                            (PP-CLR (TO:[1434..1436] to)
                              (NP (PDT:[1437..1440] all) (DT:[1441..1444] the)
                                  (JJ:[1445..1455] pancreatic)
                                  (NN:[1456..1460] cell)
                                  (NNS:[1461..1466] types)))))))))))))))
    (.:[1466..1467] .)))

;section 10 Span:1471..1516
;PMID: 10777194 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1471..1475] PMID) (::[1475..1476] :) (CD:[1477..1485] 10777194)
        (NN:[1486..1487] -LSB-) (NNP:[1487..1493] PubMed) (::[1494..1495] -)
        (NN:[1496..1503] indexed) (IN:[1504..1507] for)
        (NNP:[1508..1516] MEDLINE-RSB-)))
